|
|
||||||||
From the Minnesota Center for Health Care Ethics (A.W.P., D.E.V., K.G.G., J.E.G., T.Q.M.), Minneapolis, MN; St. Olaf College (R.G.D.), Northfield, MN; and University of South Florida (T.B.F.), Tampa, FL.
Address correspondence and reprint requests to Dr. Angela Witt Prehn, Minnesota Center for Health Care Ethics, 601 25th Avenue South, Minneapolis, MN 55454; e-mail: prehn{at}stolaf.edu.
North American researchers' perspectives on designing neurosurgical implant studies for Parkinson disease (PD) challenged the custom of holding surgical trials to less stringent evidentiary standards than other clinical studies. Researchers supported placebo surgerycontrolled trials. The framework they used to design and evaluate studies both of deep brain stimulation and cellular implants for PD may be applicable to a broad range of surgical implants for other disorders.
Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the October 24 issue to find the title link for this article.
Supported by grant NS40883 from the National Institute for Neurological Disorders and Stroke, NIH.
Disclosure: The authors report no conflicts of interest.
The content of this publication does not necessarily reflect the views or policies of the U.S. Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government.
Received October 7, 2005. Accepted in final form June 28, 2006.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |